160 related articles for article (PubMed ID: 30153792)
21. Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study.
Adawaye C; Fokam J; Kamangu E; Alio HM; Chahad AM; Susin F; Moussa AM; Bertin TH; Tidjani A; Vaira D; Moutschen M
BMC Res Notes; 2017 Nov; 10(1):589. PubMed ID: 29126456
[TBL] [Abstract][Full Text] [Related]
22. High frequency of drug resistance mutations in human immunodeficiency virus type 1-infected Korean patients treated with HAART.
Sung H; Jung YS; Kang MW; Bae IG; Chang HH; Woo JH; Cho YK
AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1223-9. PubMed ID: 17961108
[TBL] [Abstract][Full Text] [Related]
23. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study.
Di Giambenedetto S; Bracciale L; Colafigli M; Cattani P; Pinnetti C; Bacarelli A; Prosperi M; Fadda G; Cauda R; De Luca A
Antivir Ther; 2007; 12(5):835-9. PubMed ID: 17713168
[TBL] [Abstract][Full Text] [Related]
24. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
[TBL] [Abstract][Full Text] [Related]
25. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy.
Chiappini E; Galli L; Zazzi M; de Martino M
J Med Virol; 2003 Aug; 70(4):506-12. PubMed ID: 12794711
[TBL] [Abstract][Full Text] [Related]
26. Trends in drug resistance prevalence in HIV-1-infected children in Madrid: 1993 to 2010 analysis.
de Mulder M; Yebra G; Navas A; Martin L; de Jose MI; Navarro ML; de Ory SJ; Gonzalez-Granado I; Mellado MJ; Ramos JT; Holguin A
Pediatr Infect Dis J; 2012 Nov; 31(11):e213-21. PubMed ID: 22785049
[TBL] [Abstract][Full Text] [Related]
27. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR
PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218
[TBL] [Abstract][Full Text] [Related]
28. Assessing subtype and drug-resistance-associated mutations among antiretroviral-treated HIV-infected patients.
Hamkar R; Mohraz M; Lorestani S; Aghakhani A; Truong HM; McFarland W; Banifazl M; Eslamifar A; Foroughi M; Pakfetrat A; Ramezani A
AIDS; 2010 Jul; 24 Suppl 2():S85-91. PubMed ID: 20610954
[TBL] [Abstract][Full Text] [Related]
29. Assessing subtypes and drug resistance mutations among HIV-1 infected children who failed antiretroviral therapy in Kelantan, Malaysia.
Mohamad S; Deris ZZ; Yusoff NK; Ariffin TA; Shueb RH
Braz J Infect Dis; 2012; 16(3):284-8. PubMed ID: 22729198
[TBL] [Abstract][Full Text] [Related]
30. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.
Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC
J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546
[TBL] [Abstract][Full Text] [Related]
31. Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon.
Ceccarelli L; Salpini R; Moudourou S; Cento V; Santoro MM; Fokam J; Takou D; Nanfack A; Dori L; Torimiro J; Sarmati L; Andreoni M; Perno CF; Colizzi V; Cappelli G
J Med Virol; 2012 May; 84(5):721-7. PubMed ID: 22431019
[TBL] [Abstract][Full Text] [Related]
32. Minority HIV-1 resistant variants in recent infection and in patients who failed first-line antiretroviral therapy with no detectable resistance-associated mutations in Thailand.
Le Nguyen H; Pitakpolrat P; Sirivichayakul S; Delaugerre C; Ruxrungtham K
J Med Virol; 2012 May; 84(5):713-20. PubMed ID: 22431018
[TBL] [Abstract][Full Text] [Related]
33. HIV type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Côte d'Ivoire.
Hanson DL; Adjé-Touré C; Talla-Nzussouo N; Eby P; Borget MY; Kouadio LY; Celestin BE; Tossou O; Eholie S; Kadio A; Chorba T; Nkengasong JN
AIDS Res Hum Retroviruses; 2009 May; 25(5):489-95. PubMed ID: 19388820
[TBL] [Abstract][Full Text] [Related]
34. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
[TBL] [Abstract][Full Text] [Related]
35. The association between primary antiretroviral resistance and HAART virologic failure in a developing set.
Gagliani LH; Alkmim Maia WT; Sá-Filho D; Janini LM; Sucupira MC; Caseiro MM; Diaz RS
AIDS Res Hum Retroviruses; 2011 Mar; 27(3):251-6. PubMed ID: 20977353
[TBL] [Abstract][Full Text] [Related]
36. Short communication: low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia.
Tee KK; Kamarulzaman A; Ng KP
AIDS Res Hum Retroviruses; 2006 Feb; 22(2):121-4. PubMed ID: 16478392
[TBL] [Abstract][Full Text] [Related]
37. Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics.
Kühnert D; Kouyos R; Shirreff G; Pečerska J; Scherrer AU; Böni J; Yerly S; Klimkait T; Aubert V; Günthard HF; Stadler T; Bonhoeffer S;
PLoS Pathog; 2018 Feb; 14(2):e1006895. PubMed ID: 29462208
[TBL] [Abstract][Full Text] [Related]
38. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L
Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
[TBL] [Abstract][Full Text] [Related]
39. Drug resistance among chronic HIV-1-infected patients naïve for use of anti-retroviral therapy in Sao Paulo city.
Gonsalez CR; Alcalde R; Nishiya A; Barreto CC; Silva FE; de Almeida A; Mendonça M; Ferreira F; Fernandes SS; Casseb J; Duarte AJ
Virus Res; 2007 Nov; 129(2):87-90. PubMed ID: 17686543
[TBL] [Abstract][Full Text] [Related]
40. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
